Duopharma Biotech Berhad (KLSE:DPHARMA)
1.030
-0.050 (-4.63%)
At close: Nov 20, 2026
Duopharma Biotech Berhad Revenue
Duopharma Biotech Berhad had revenue of 210.05M MYR in the quarter ending September 30, 2026, a decrease of -5.59%. This brings the company's total for the last twelve months to 916.98M, up 1.81% year-over-year. In the year 2025, Duopharma Biotech Berhad had annual revenue of 931.69M with 14.50% growth. That makes Duopharma Biotech Berhad the 16,746th largest company in the world by revenue and 220th in Malaysia.
Revenue (ttm)
916.98M
Revenue Growth
+1.81%
P/S Ratio
1.08
Revenue / Employee
468.56K
Employees
1,957
Market Cap
990.80M
Revenue by Geography
- Malaysia 871.83M 93.6%
- Export 59.87M 6.4%
Fiscal year ended Dec 31, 2025 See the full Duopharma Biotech Berhad breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 931.69M | 118.00M | 14.50% |
| Dec 31, 2024 | 813.70M | 108.97M | 15.46% |
| Dec 31, 2023 | 704.73M | 8.01M | 1.15% |
| Dec 31, 2022 | 696.72M | 57.54M | 9.00% |
| Dec 31, 2021 | 639.18M | 69.27M | 12.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DXN Holdings Bhd. | 1.92B |
| Y.S.P. Southeast Asia Holding Berhad | 370.79M |
| Kotra Industries Berhad | 233.17M |
| Rhone Ma Holdings Berhad | 228.88M |
| Sunzen Group Berhad | 93.59M |
| PeterLabs Holdings Berhad | 63.47M |
| Nova Wellness Group Berhad | 49.74M |
| Bioalpha Holdings Berhad | 10.93M |